ASCO 2025 Annual Meeting

The American Society of Clinical Oncology's (ASCO) 2025 Annual Meeting will be held May 30 – June 3, 2025, both in-person in Chicago, IL, and virtually. Thousands of oncology professionals from around the world will attend ASCO 2025, which provides updates on new clinical advances in every area of cancer research and strives to advance equitable cancer care through international innovation. This year's theme is The Place to Be and will feature more than 200 sessions and 5,000 abstracts.

See the full program »

The Mass General Cancer Center will have a strong presence at ASCO 2025, with dozens of leaders sharing their latest research in abstract presentations, poster sessions, discussions and more.

Friday, May 30, 2025

ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?
Case-Based Panel, 1:00 p.m. - 2:00 p.m. CDT – Arie Crown Theater
Moderator: Priyadarshini Pathak, MBBS

Who, What, How: Best Practices for the Development of the Multidisciplinary Immunotherapy Toxicity Service
Education Session, 1:00 p.m. - 1:12 p.m. CDT – E350
Presenter: Kerry Reynolds, MD

Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Randomized Controlled Trial
Oral Abstract (11000) Session, 1:00 p.m. - 1:12 p.m. CDT – S504
Presenter: Jamie Jacobs, PhD

Randomized Trial of a Supportive Oncology Care at Home Intervention for Patients With Cancer Receiving Curative Treatment
Oral Abstract (11003) Session, 1:36 p.m. - 1:48 p.m. CDT – S504
Senior Authors: Joseph Greer, PhD, Jennifer Temel, MD, and Areej El-Jawahri, MD

Optimizing Targeted Therapies and Endocrine Combinations With Molecular Markers
Education Session, 4:30 p.m. - 4:42 p.m. CDT – Hall D2
Presenter: Seth Wander, MD, PhD

Immunological Correlates From Phase I Study of CARv3-TEAM-E in Patients With Recurrent Glioblastoma (GBM): INCIPIENT Trial
Oral Abstract (2008) Session, 5:09 p.m. - 5:21 p.m. CDT – S100bc
Presenter: Bryan Choi, MD, PhD

Saturday, May 31, 2025

Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients (pts) With Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): 2-year (yr) Follow-up of STARGLO
Rapid Oral Abstract (7015) Session, 9:00 a.m.- 9:06 a.m. CDT – E540a
Presenter: Jeremy Abramson, MD

Esophageal Cancer: Current Standards in an Ever-Changing Treatment Landscape
Case-Based Panel, 1:15 p.m.- 1:55 p.m. CDT – Hall D1
Moderator: Samuel Klempner, MD

Safety and Tolerability of Intraventricular CARv3-TEAM-E T Cells Following Lymphodepleting Chemotherapy in Recurrent Glioblastoma: INCIPIENT Trial
Rapid Oral Abstract (2017) Session, 3:42 p.m.- 3:48 p.m. CDT – S102
Presenter: Elizabeth Gerstner, MD

Sunday, June 1, 2025

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab (SG/P) in Patients With Early-stage Triple-negative Breast Cancer: Results From the NeoSTAR Trial
Rapid Oral Abstract (511) Session, 8:12 a.m.- 8:18 a.m. CDT – Hall B1
Presenter: Rachel Abelman, MD

Blended Survivorship and Palliative Care for Patients With Advanced Lung Cancer Receiving Targeted Therapy: An Open Pilot
Poster (1634) Session, 9:00 a.m.- 12:00 p.m. CDT – Hall A
Author: Laura Petrillo, MD

Harmony in Healing: Music, Mindfulness, and Mental Health
Oral Abstract Session, 11:21 a.m.- 11:33 a.m. CDT – S100bc
Discussant: Lara Traeger, PhD

Romiplostim for Chemotherapy-induced Thrombocytopenia (CIT) in Colorectal, Gastroesophageal, and Pancreatic Cancers: A Global, Phase 3, Randomized, Placebo-controlled Trial (RCT)
Oral Abstract Session, 11:57 a.m.- 12:09 p.m. CDT – S100bc 
Presenter: Hanny Al-Samkari, MD

Plenary Session
3:25 p.m. CDT – Hall B1 
Discussant: Samuel Klempner, MD

Late Complications of Immunotherapies
Education Session, 4:45 p.m.- 5:00 p.m. CDT – E451 
Presenter: Jeremy Abramson, MD

Monday, June 2, 2025

State of the Science: What Do We Know Now About Early-Onset Cancer and Where Do We Need to Go?
Education Session, 8:28 a.m. - 8:45 a.m. CDT – S100bc
Presenter: Andrew Chan, MD, MPH

Evaluation of De Novo Oligometastatic, Oligorecurrent, and Oligoprogressive Prostate Cancer Patients Managed With Radiation Therapy: A Multi-institution, Real-world Dataset
Poster (5099) Session, 9:00 a.m. - 12:00 p.m. CDT – Hall A
Poster: Sophia Kamran, MD

Needle in the Haystack: Precision Screening for Lung Cancer and Role of Artificial Intelligence
Education Session, 11:54 a.m. - 12:06 p.m. CDT – Arie Crown Theater
Presenter: Florian Fintelmann, MD

Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: What Can We Agree On?
Case-Based Panel, 1:15 p.m. - 1:55 p.m. CDT – E450a
Panelist: Genevieve Boland, MD, PhD

Examining the Relationship Between Multi-agent Immunosuppressive Therapy for Immune-related Adverse Events (irAE) and Infectious Complications
Poster (2658) Session, 1:30 p.m. - 4:30 p.m. CDT – Hall A
Author: Tristan Lim, MD, MS

Pharmacist-led Medication Reconciliation Televisit (MRT) for Phase 1 Oncology Clinical Trials: A Telemedicine Model
Oral Abstract (1500) Session, 3:00 p.m. - 3:12 p.m. CDT – S100bc
Presenter: Sarah O'Neill, PharmD

Local Therapy Options in Hepatobiliary Malignancies
Education Session, 5:15 p.m. - 5:30 p.m. CDT – E451
Presenter: Jennifer Yon-Li Wo, MD

Breaking New Ground in Small Cell Lung Cancer: BiTE, TriTE and Chemoimmunotherapy
Oral Abstract Session, 5:36 p.m. - 5:48 p.m. CDT – Arie Crown Theater
Presenter: Catherine Meador, MD, PhD

Tuesday, June 3, 2025

Primary Results of a Phase 2 Study of Cisplatin-sensitized Radiation Therapy and Pembrolizumab for Unresectable Vulvar Cancer
Rapid Oral Abstract (5511) Session, 8:12 a.m. - 8:18 a.m. CDT – S100bc
Presenter: Oladapo Yeku, MD, PhD

The Future of T-Cell Therapy
Education Session, 8:30 a.m. - 8:45 a.m. CDT – S100a
Presenter: Donald Lawrence, MD

Randomized Phase II Study of Neoadjuvant (neoadj) Anti-PD-1 Dostarlimab (D) vs. D + Anti-TIM-3 Cobolimab (C) in High-risk Resectable Melanoma (mel) (NEO-MEL-T): Primary Analysis
Oral Abstract (LBA9504) Session, 10:57 a.m. - 11:09 a.m. CDT – S100a
Presenter: Meghan Mooradian, MD